Allos Therapeutics Files Shelf Registration Statement
March 05 2004 - 5:59PM
PR Newswire (US)
Allos Therapeutics Files Shelf Registration Statement WESTMINSTER,
Colo., March 5 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
announced today that it has filed a Form S-3 shelf registration
with the Securities and Exchange Commission (SEC). The shelf
registration, when declared effective by the SEC, will allow the
company to raise up to $75 million through the sale of various
securities in one or more offerings in the future. Specific terms
and prices will be determined at the time of any offering. A
registration statement relating to the securities listed in the
shelf registration has been filed with the SEC, but has not yet
become effective. These securities may not be sold, nor may offers
to buy such securities be accepted, prior to the time that the
registration statement becomes effective. This press release shall
not constitute an offer to sell or the solicitation of an offer to
buy, nor shall there be any sale of these securities, in any state
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state. A written prospectus, when available, meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended, may be obtained fromthe company at 11080 CirclePoint Road,
Suite 200, Westminster, Colorado 80020, Attention: Investor
Relations. Allos Therapeutics, Inc. is a biopharmaceutical company
focused on developing and commercializing innovative drugs for
improving cancer treatments. The company's lead clinical candidate,
RSR13, is a synthetic small molecule that has the potential to
sensitize hypoxic (oxygen deprived) tumor tissues and enhance the
efficacy of standard radiation therapy. In addition, Allos is
developing PDX, an injectable small molecule chemotherapeutic agent
that has a superior potency and toxicity profile relative to
methotrexate and other dihydrofolate reductase, or DHFR,
inhibitors. For more information, please visit the company's web
site at: http://www.allos.com/. This news release contains certain
forward-looking statements that involve risks and uncertainties.
Such forward-looking statements include statements regarding the
sale of securities under the shelf registration statement. Such
statements are only predictions and the company may be unable to
complete any sale of securities under the shelf registration
statement. Factors that may cause such differences include market
conditions and others that are more fully discussed in the
company's periodic reports and other filings with the SEC.
DATASOURCE: Allos Therapeutics, Inc. CONTACT: Monique M. Greer VP,
Corporate Communications and Investor Relations of Allos
Therapeutics, Inc., +1-720-540-5241, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics (MM) News Articles